In patients with chronic kidney disease (CKD) and iron-deficiency anaemia, the orally administered ferric maltol appears to yield meaningful and sustained increases in haemoglobin and iron indices, with a low rate of treatment discontinuation due to adverse events, according to the results of the phase III AEGIS-CKD trial and open-label extension.
The inclusion of a clinical oncology pharmacist into an ambulatory care pharmacy in paediatric haematology–oncology and transplant clinic results in reduced adverse events and fewer readmission into the hospital, a study has shown.
Certain therapies used for rheumatic diseases, including rituximab, are associated with worse outcomes for COVID-19 and reduced immune response after COVID-19 vaccination in patients with rheumatic diseases, according to two studies presented at the virtual EULAR 2021 Congress.
The physical and chemical stability of cytarabine diluted in 0.9% NaCl in polypropylene syringes is at its highest at 2–8 °C, a recent study in Tunisia has found. The 1-mg/mL solution demonstrates better stability at 25 °C relative to those at higher concentrations (5 and 10 mg/mL).
Treatment with the fully human anti-IL17 monoclonal antibody secukinumab resulted in fewer, and a longer time to, disease flares in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), results of the phase III JUNIPERA trial showed.
Once-weekly injection of the GLP-1* agonist semaglutide, on top of endoscopic sleeve gastroplasty (ESG), led to a greater weight loss and better glucose control vs ESG alone in patients with diabetes and excess weight but are not candidates for bariatric surgery, a new study has shown.
Eligible patients with rheumatic diseases (PRDs) are strongly urged to get vaccinated against COVID-19, and the vaccine may be administered while on immunomodulatory therapy, preferably during an inactive disease state, and without requiring testing for postvaccination antibody titres, according to recommendations from the Singapore Chapter of Rheumatologists.